EGFR and skin squamous cell carcinoma: The systemic therapies (platinum base and EGFR) most amplie to cSCC [20,38] typically present recurrence, limited responses, and early progression, in contrast to Cemiplimab, where fatal adverse events are rare, with high response rates and being safe and well tolerated.